Capital Research holds 6.8% of Vertex Pharma

Capital Research Global Investors filed a Schedule 13G/A reporting beneficial ownership of 17,319,044 shares of Vertex Pharmaceuticals Inc. common stock, representing 6.8% of the 253,718,831 shares believed to be outstanding as of the event date.

Rhea-AI Filing Summary

Capital Research Global Investors filed a Schedule 13G/A reporting beneficial ownership of 17,319,044 shares of Vertex Pharmaceuticals Inc. common stock, representing 6.8% of the 253,718,831 shares believed to be outstanding as of the event date.

The filer reports sole voting power over 17,303,696 shares and sole dispositive power over 17,319,044 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Vertex.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Capital Research Global Investors report in Vertex (VRTX)?

Capital Research Global Investors reports beneficial ownership of 17,319,044 Vertex shares. This represents 6.8% of Vertex Pharmaceuticals Inc.’s common stock, based on 253,718,831 shares believed to be outstanding as of the reported event date in the Schedule 13G/A filing.

What percentage of Vertex (VRTX) common stock is owned according to this Schedule 13G/A?

Capital Research Global Investors reports owning 6.8% of Vertex’s common stock. The filing states this percentage is based on 253,718,831 Vertex shares believed to be outstanding, giving Capital Research Global Investors a significant but minority ownership position in the company.

How many Vertex (VRTX) shares can Capital Research Global Investors vote and dispose of?

Capital Research Global Investors reports sole voting power over 17,303,696 shares. The filer also reports sole dispositive power over 17,319,044 shares, with no shared voting or shared dispositive power, indicating centralized control over how these shares are voted and potentially sold.

Is Capital Research Global Investors seeking to influence control of Vertex (VRTX)?

The filing states the Vertex shares were acquired in the ordinary course of business. Capital Research Global Investors certifies they were not acquired and are not held for the purpose of changing or influencing control of Vertex Pharmaceuticals, outside activities solely related to certain nomination rules.

What type of filing did Capital Research Global Investors submit for Vertex (VRTX)?

Capital Research Global Investors submitted an Amendment No. 1 to Schedule 13G. This beneficial ownership report covers Vertex Pharmaceuticals Inc. common stock and updates the market on Capital Research Global Investors’ 6.8% ownership position and related voting and dispositive powers.

Who signed the Schedule 13G/A related to Vertex (VRTX) and in what capacity?

The Schedule 13G/A was signed by Jae Won Chung. The signer is identified as Vice President and Senior Counsel II of Capital Research and Management Company, certifying that the information provided about Capital Research Global Investors’ Vertex holdings is true, complete, and correct.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 10:25 AM EST Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Vertex Pharmaceuticals Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

92532F100

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 92532F100

1

Names of Reporting Persons

Capital Research Global Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 17,303,696.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 17,319,044.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

17,319,044.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Vertex Pharmaceuticals Inc.
(b)	Address of issuer's principal executive offices: 50 Northern Avenue, Boston, MA 02210, United States of America
Item 2.
(a)	Name of person filing: Capital Research Global Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 92532F100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 17,319,044 ** **Capital Research Global Investors ("CRGI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CRGI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital Research Global Investors." CRGI is deemed to be the beneficial owner of 17,319,044 shares or 6.8% of the 253,718,831 shares believed to be outstanding.
(b)	Percent of class: 6.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 17,303,696
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 17,319,044
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital Research Global Investors

Signature:	Jae Won Chung
Name/Title:	Vice President and Senior Counsel II, Capital Research and Management Company
Date:	02/05/2026